Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANL NASDAQ:CLYM NASDAQ:IPA NASDAQ:ONCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$1.46+1.7%$1.58$1.10▼$3.89$53.51M-0.956,641 shs4,210 shsCLYMClimb Bio$1.45+3.6%$1.32$1.05▼$8.79$97.99M-0.11204,297 shs145,674 shsIPAImmunoPrecise Antibodies$1.64-1.2%$1.22$0.27▼$2.41$75.69M0.492.14 million shs1.01 million shsONCYOncolytics Biotech$0.99-2.9%$0.80$0.33▼$1.53$96.43M1.091.31 million shs537,614 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye0.00%+1.04%-7.09%-24.02%-58.43%CLYMClimb Bio0.00%0.00%+13.28%+14.17%+144,999,900.00%IPAImmunoPrecise Antibodies0.00%-24.07%+22.85%+257.22%+107.86%ONCYOncolytics Biotech0.00%-5.71%+9.88%+80.00%-4.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANLAdlai Nortye1.7561 of 5 stars3.05.00.00.00.00.00.0CLYMClimb Bio2.3381 of 5 stars3.60.00.00.00.02.51.3IPAImmunoPrecise Antibodies2.0204 of 5 stars3.53.00.00.01.80.00.6ONCYOncolytics Biotech2.4429 of 5 stars3.45.00.00.02.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 2.00Hold$9.00518.56% UpsideCLYMClimb Bio 3.25Buy$9.00520.69% UpsideIPAImmunoPrecise Antibodies 3.00Buy$4.00143.90% UpsideONCYOncolytics Biotech 2.75Moderate Buy$4.33337.71% UpsideCurrent Analyst Ratings BreakdownLatest ANL, ONCY, IPA, and CLYM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025CLYMClimb BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$10.006/2/2025ANLAdlai NortyeHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/22/2025CLYMClimb BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/22/2025CLYMClimb BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$7.005/21/2025ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/16/2025ONCYOncolytics BiotechJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M10.74N/AN/A$0.69 per share2.11CLYMClimb BioN/AN/AN/AN/A$3.15 per shareN/AIPAImmunoPrecise Antibodies$17.59M4.30N/AN/A$0.93 per share1.76ONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$51.87MN/A0.00N/AN/AN/AN/AN/A8/8/2025 (Estimated)CLYMClimb Bio-$73.90M-$2.38N/AN/AN/AN/A-43.95%-42.94%8/13/2025 (Estimated)IPAImmunoPrecise Antibodies-$20.13M-$0.68N/AN/AN/A-122.10%-40.62%-22.19%9/15/2025 (Estimated)ONCYOncolytics Biotech-$23.14M-$0.29N/AN/AN/AN/A-313.77%-130.19%8/7/2025 (Estimated)Latest ANL, ONCY, IPA, and CLYM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CLYMClimb Bio-$0.19N/AN/AN/AN/AN/A8/7/2025Q2 2025ONCYOncolytics Biotech-$0.10N/AN/AN/AN/AN/A7/29/2025Q4 2025IPAImmunoPrecise Antibodies-$0.02-$0.04-$0.02-$0.04$7.89 million$5.06 million5/14/2025Q1 2025CLYMClimb Bio-$0.15-$0.31-$0.16-$0.31N/AN/A5/14/2025Q1 2025ONCYOncolytics Biotech-$0.09-$0.06+$0.03-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai Nortye0.021.411.41CLYMClimb BioN/A14.2514.25IPAImmunoPrecise Antibodies0.492.082.11ONCYOncolytics BiotechN/A3.203.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%CLYMClimb Bio69.76%IPAImmunoPrecise Antibodies6.70%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/ACLYMClimb Bio0.80%IPAImmunoPrecise Antibodies6.83%ONCYOncolytics Biotech0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12736.90 millionN/ANot OptionableCLYMClimb Bio967.58 million67.04 millionN/AIPAImmunoPrecise Antibodies8046.15 million43.00 millionNot OptionableONCYOncolytics Biotech3097.41 million97.31 millionNot OptionableANL, ONCY, IPA, and CLYM HeadlinesRecent News About These CompaniesAnalysts Set Oncolytics Biotech Inc. (NASDAQ:ONCY) Target Price at $4.33August 2 at 2:06 AM | americanbankingnews.comOncolytics Biotech (ONCY) Projected to Post Earnings on ThursdayJuly 31 at 3:38 AM | marketbeat.comOncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by BrokeragesJuly 30, 2025 | marketbeat.comOncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-EndJuly 29, 2025 | prnewswire.comOncolytics Biotech (NASDAQ:ONCY) Stock Price Up 3.8% - Time to Buy?July 29, 2025 | marketbeat.comKey Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future PotentialJuly 25, 2025 | cantechletter.comCCancer Surge Meets Funding Crunch as Breakthrough Biotechs Line Up Milestones in 2025July 24, 2025 | baystreet.caOncolytics Biotech Inc.: Oncolytics Biotech Regains Compliance with Nasdaq Trading RulesJuly 24, 2025 | finanznachrichten.deHigh‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy HeadwindsJuly 24, 2025 | newswire.caOncolytics Biotech Highlights Pelareorep’s Potential in Pancreatic Cancer at KOL EventJuly 23, 2025 | tipranks.comKey Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future PotentialJuly 23, 2025 | prnewswire.comOncolytics Biotech Regains Nasdaq Compliance as of July 22, 2025July 22, 2025 | tipranks.comOncolytics Biotech® Regains Compliance with Nasdaq Trading RulesJuly 22, 2025 | prnewswire.comOncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor TypesJuly 16, 2025 | prnewswire.comOncolytics Biotech Inc. (ONCY) - Yahoo Finance CanadaJuly 11, 2025 | ca.finance.yahoo.comUSA News Group: Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step UpJuly 10, 2025 | finanznachrichten.deOncolytics Biotech to Host Webinar on Pelareorep’s Potential in Cancer TreatmentJuly 10, 2025 | tipranks.comOncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal CancersJuly 10, 2025 | prnewswire.comOncolytics Biotech Highlights Promising Pelareorep Data in Cancer TreatmentJuly 10, 2025 | theglobeandmail.comGlobal Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies - The Globe and MailJuly 9, 2025 | theglobeandmail.comOncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling StudiesJuly 8, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendAmazon's Prime Day Pullback Meets Bullish Golden Cross SignalBy Gabriel Osorio-Mazilli | July 8, 2025View Amazon's Prime Day Pullback Meets Bullish Golden Cross SignalBig 3 Telecom Wars: 2 Solid Showings, 1 Huge Winner in Q2By Leo Miller | July 29, 2025View Big 3 Telecom Wars: 2 Solid Showings, 1 Huge Winner in Q2Goldman, Morgan Stanley, & BofA: Diverging Paths After EarningsBy Sam Quirke | July 21, 2025View Goldman, Morgan Stanley, & BofA: Diverging Paths After Earnings3 Fast Food Stocks That Won’t Give You Indigestion Right NowBy Brian O'Connell | July 16, 2025View 3 Fast Food Stocks That Won’t Give You Indigestion Right NowANL, ONCY, IPA, and CLYM Company DescriptionsAdlai Nortye NASDAQ:ANL$1.46 +0.03 (+1.75%) Closing price 08/1/2025 03:57 PM EasternExtended Trading$1.46 0.00 (0.00%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Climb Bio NASDAQ:CLYM$1.45 +0.05 (+3.57%) As of 08/1/2025 04:00 PM EasternClimb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.ImmunoPrecise Antibodies NASDAQ:IPA$1.64 -0.02 (-1.20%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.58 -0.05 (-3.35%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Oncolytics Biotech NASDAQ:ONCY$0.99 -0.03 (-2.94%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.00 +0.01 (+1.52%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
